Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ketogenic diet in rheumatoid arthritis, psoriatic arthritis and psoriasis: A scoping review of clinical and mechanistic evidence.

Autoimmunity reviews·2026

Same author

Heart Failure and Cognitive Impairment: A Narrative Review.

ESC heart failure·2026

Same author

Frailty and Heart Failure: An Integrated Review of a Bidirectional Relationship.

ESC heart failure·2026

Same author

Penile Rehabilitation After Surgery for Prostate Cancer: An Umbrella Review on Traditional Approaches and Novel Perspectives.

Journal of clinical medicine·2026

Same author

Effect of breastfeeding on cardiometabolic risk in patients with polycystic ovary syndrome.

Journal of endocrinological investigation·2026

Same author

Mid-pregnancy serum chemerin levels predict persistence of postpartum hypertension in patients with polycystic ovary syndrome.

European journal of endocrinology·2026

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Chronic sildenafil in men with diabetes and erectile dysfunction.

Antonio Aversa¹, Roberto Bruzziches, Cristiana Vitale

¹University of Rome La Sapienza, Dept of Medical Pathophysiology, Viale Policlinico 155 - 00161 Rome, Italy.

Expert Opinion on Drug Metabolism & Toxicology

|June 2, 2007

Summary

Diabetic men often experience erectile dysfunction due to diabetes complications. Daily phosphodiesterase type-5 inhibitors may offer a new rehabilitative treatment for sexual dysfunction in these patients.

Related Experiment Videos

Last Updated: Jul 14, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Urology
Endocrinology
Diabetology

Background:

Erectile dysfunction (ED) is a common neurovascular complication in diabetes mellitus, affecting nearly 50% of diagnosed men within 6 years.
Diabetes-related ED stems from molecular abnormalities including protein kinase C (PKC) activation, oxidative stress, and advanced glycosylation end products, leading to penile cell dysfunction.

Purpose of the Study:

To investigate the potential rehabilitative effects of daily phosphodiesterase type-5 inhibitor (PDE5i) therapy for erectile dysfunction in diabetic patients.
To evaluate PDE5i as a potentially curative or rehabilitative approach for sexual dysfunction in the context of diabetes.

Main Methods:

Ongoing clinical trials are assessing the efficacy of daily administration of phosphodiesterase type-5 inhibitors.
The study design focuses on demonstrating rehabilitative effects beyond symptomatic relief.

Main Results:

The response rate to standard oral therapies like sildenafil is notably lower in diabetic men compared to other populations.
Current therapeutic alternatives, such as intracavernous injections, are not curative for ED.

Conclusions:

Daily PDE5i therapy presents a promising avenue for achieving sexual rehabilitation in diabetic men with ED.
This approach may offer significant advantages over current intracavernosal treatments, potentially leading to long-term functional recovery.